CEO and scientist presents Immune Suppressive AAV Based Gene Therapy for Repeat Dosing
The Gene Therapy Next Generation Vector Summit is an annual event dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.
Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups are invited to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely.
In her segment, “EVADER™ Immune Suppressive AAV Based Gene Therapy for Repeat Dosing” CEO Genine Winslow will speak on the clinical challenges addressed by EVADER technology, scalable production of EVADER vectors, and anti-capsid immune reduction by EVADER vectors.
For more information on the Gene Therapy Next Generation Vector Summit and Genine’s presentation, visit https://www.einpresswire.com/article/582019074/chameleon-biosciences-founder-to-speak-at-next-generation-gene-therapy-vectors-summit-2022-in-boston.